News | News By Subject | News by Disease News By Date | Search News

Ankylosing spondylitis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Top 10 Best-Selling Biotech Drugs     10/2/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Centocor, Inc. (JNJ) New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis     11/8/2007
Abbott Laboratories (ABT)' HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment Of Ankylosing Spondylitis     7/31/2006
Abbott Laboratories (ABT)'s HUMIRA(R) (Adalimumab) Receives Positive Opinion From European Medicines Evaluation Agency For The Treatment Of Ankylosing Spondylitis     4/28/2006
Tanabe Seiyaku Company , Centocor, Inc. (JNJ) Revise Licensing Agreement On Remicade, Anti TNF-alpha Monoclonal Antibody Preparation     2/1/2005
Preliminary Data From Two Clinical Trials Demonstrate Abbott Laboratories' (ABT) HUMIRA(R) (Adalimumab) Improved Symptoms Of Psoriatic Arthritis And Ankylosing Spondylitis     6/14/2004
Centocor, Inc. (JNJ) And Schering-Plough Corporation (SGP) Release: Results From Clinical Trials Of REMICADE(R) Demonstrate Clinical Benefit And Sustained Efficacy In Ankylosing Spondylitis     6/14/2004

News from Around the Web

Press Releases
Celgene International Sárl (CELG) Release: Phase II Study Evaluating Apremilast as an Oral Treatment for Patients with Ankylosing Spondylitis Presented at Celgene International Sárl (CELG)     11/8/2011
Centocor, Inc. (JNJ): New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings     11/8/2007
Abbott Laboratories (ABT) Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis     11/8/2007
Schering-Plough Corporation (SGP) and Centocor, Inc. (JNJ) REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation     6/15/2007
Amgen (AMGN) Release: Data Shows ENBREL Provides Sustained Clinical Improvements For People With Ankylosing Spondylitis For Up To Three Years     11/13/2006
New Phase III Data Demonstrate That Abbott Laboratories (ABT)'s HUMIRA(R) (Adalimumab) Sustained Reduction In Signs And Symptoms Through One Year In Patients With Ankylosing Spondylitis     6/23/2006
Centocor, Inc. (JNJ) Release: New MRI Data Shows REMICADE Significantly Decreases Spinal Inflammation In Patients With Ankylosing Spondylitis; Chronic Inflammation May Be Associated With Decreased Spinal Mobility     10/21/2004
Ruhr University Release: New MRI Data Shows Treatment With ENBREL May Stop The Progression Of Structural Damage In Patients With Ankylosing Spondylitis     10/19/2004
Centocor, Inc. (JNJ) Release: New MRI Data Show REMICADE(R) Significantly Decreases Spinal Inflammation In Patients With Ankylosing Spondylitis     10/18/2004
Wyeth Pharmaceuticals' (WYE) ENBREL Receives European Union Approval For The Treatment Of Ankylosing Spondylitis     1/20/2004

//-->